PRGO.TA - Perrigo Company plc

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
22,080.00
-220.00 (-0.99%)
As of 12:20PM IST. Market open.
Stock chart is not supported by your current browser
Previous Close22,300.00
Open21,970.00
Bid22,040.00 x 7100
Ask22,070.00 x 29700
Day's Range21,970.00 - 22,220.00
52 Week Range21,750.00 - 32,500.00
Volume39,608
Avg. Volume96,137
Market Cap28.295B
Beta (3Y Monthly)0.59
PE Ratio (TTM)25,034.01
EPS (TTM)0.88
Earnings DateN/A
Forward Dividend & Yield2.82 (1.26%)
Ex-Dividend Date2018-11-29
1y Target Est86.00
  • PR Newswire3 days ago

    Perrigo Announces the Launch of an AB Rated Generic Version of Topicort® Topical Spray 0.25%

    TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the treatment of plaque psoriasis in patients 18 years of age or older. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This launch exemplifies Perrigo's ongoing commitment to developing quality, high value alternatives in important treatment categories.

  • GlobeNewswire9 days ago

    Sol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo

    Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for this generic product candidate. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidate in the United States.

  • Perrigo Announces Patent Litigation Settlement For The Generic Version Of Sernivo® Spray, 0.05%
    PR Newswire15 days ago

    Perrigo Announces Patent Litigation Settlement For The Generic Version Of Sernivo® Spray, 0.05%

    TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma LLC. Terms of the settlement are confidential. Sernivo® (betamethasone dipropionate, 0.05%) Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.  Annual market sales for the 12 months ending September 2018 were approximately $13 million as measured by IQVIA™. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy.

  • Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%
    PR Newswire16 days ago

    Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%

    TASE: PRGO) today announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Diclofenac sodium gel, 3% was developed through a pharmaceutical development partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The product is manufactured by Perrigo and shipping to customers has commenced.

  • Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%
    PR Newswire17 days ago

    Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Our R&D team continues its efforts to secure regulatory approvals for important new products. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network.

  • David Einhorn's Top 4 Sells in 3rd Quarter
    GuruFocus.com27 days ago

    David Einhorn's Top 4 Sells in 3rd Quarter

    Top sells include Mylan and GM. Investor also axed Apple and Micron

  • GlobeNewswirelast month

    Sol-Gel Technologies Reports Third Quarter 2018 Financial Results

    NESS ZIONA, Israel, Nov. 13, 2018 -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying,.

  • GuruFocus.comlast month

    Stocks That Fell to 3-Year Lows in the Week of Nov. 9

    General Electric Co., Vodafone Group PLC, Ctrip.com International Ltd. and Perrigo Co. PLC have declined to their respective 3-year lows

  • GuruFocus.comlast month

    Perrigo Co Plc (PRGO) CEO Murray S Kessler Bought $1 million of Shares

    CEO of Perrigo Co Plc (NYSE:PRGO) Murray S Kessler bought 15,683 shares of PRGO on 11/09/2018 at an average price of $63.79 a share.

  • Barrons.comlast month

    The Biggest Loser: Perrigo Tumbles 16%

    Perrigo lost $12.26, or 16.3%, to $62.88. Perrigo lowered its full-year guidance, as it now sees EPS between $4.45 and $4.65, down from $4.75 to $4.95, on revenue of $4.72 billion, down from $4.8 billion to $4.9 billion. Leerink’s Ami Fada reiterated a Market Perform rating on the stock, writing that “once again the top line continues to be weak and 2018 guidance was lowered primarily due to the prescription segment.” While this “shouldn’t be a complete surprise given prescription trends,” she expected the stock to be weak on the news.

  • GuruFocus.comlast month

    3 Stocks Move Thursday

    Financial results impact Herc Holdings, Perrigo and Roku

  • Reuterslast month

    US STOCKS-S&P 500 edges lower ahead of Fed decision

    The S&P 500 inched lower on Thursday, as disappointing results from a slew of companies, including Qualcomm Inc, countered gains in bank stocks ahead of the Federal Reserve's interest rate decision. Among the biggest decliners on the benchmark index were Perrigo Co, Wynn Resorts Ltd and D.R. Horton Inc, all falling on disappointing quarterly results.

  • Perrigo Company PLC (PRGO) Q3 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Perrigo Company PLC (PRGO) Q3 2018 Earnings Conference Call Transcript

    PRGO earnings call for the period ending September 29, 2018.

  • Barrons.comlast month

    Midday Movers: Perrigo Plunges, TripAdvisor Soars, Tesla Advances

    STOCKSTOWATCHTODAY BLOG One day after the Dow Jones Industrial Average rose more than 500 points, the Dow has advanced 55.40 points, or 0.2%, to 26,235.70, while the S&P 500 has dipped 0.1%, to 55.40, and the Nasdaq Composite has declined 0.

  • Reuterslast month

    US STOCKS-Weak results keep S&P, Nasdaq lower ahead of Fed decision

    The S&P 500 and the Nasdaq edged lower on Thursday, as weak earnings reports and caution ahead of the Federal Reserve's interest rate decision stalled a rally from the previous session, which was spurred by the outcome for midterm elections. Among the biggest deliners on the S&P 500 were Perrigo Co , Wynn Resorts Ltd and D.R. Horton Inc, all falling on disappointing quarterly results.

  • The Wall Street Journallast month

    [$$] Perrigo Strikes Out Again

    Perrigo shares fell sharply after the report and are down nearly 30% so far this year. Perrigo said on the call that problems included an “absence of new products, price erosion in authorized generic products and customer-service challenges resulting in lower sales volumes.” Perrigo plans to sell or spin off the generics business, but it is hard to imagine a buyer will pay a good price to own what is clearly a troubled operation. Perrigo won’t provide financial guidance for 2019 until February, but another decline would mark three consecutive years of falling profits.

  • Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down
    Zackslast month

    Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down

    Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.

  • Reuterslast month

    US STOCKS-Wall St dips as weak earnings dampen surge from midterm elections

    U.S. stocks edged lower on Thursday, as a clutch of weak earnings reports punctured a rally from the previous session, which was spurred by the outcome for midterm elections. Wynn Resorts Ltd, Perrigo Co and D.R. Horton Inc were the biggest losers on the S&P 500, all falling after reporting disappointing quarterly results. Qualcomm Inc dropped 7.1 percent after the chipmaker forecast sales revenue for the holiday shopping quarter below analysts' estimates, as it took a hit from the loss of chip sales to Apple Inc.

  • Perrigo (PRGO) Q3 Earnings Beat Estimates
    Zackslast month

    Perrigo (PRGO) Q3 Earnings Beat Estimates

    Perrigo (PRGO) delivered earnings and revenue surprises of 3.81% and -3.23%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • CNBClast month

    Stocks making the biggest move premarket: ARRS, COMM, PRGO, DHI, PRTY & more

    These are the stocks posting the largest moves before the bell.

  • Associated Presslast month

    Perrigo: 3Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 49 cents. Earnings, adjusted for one-time gains and costs, came to $1.09 per share. The results beat Wall Street expectations. The average ...

  • Perrigo Company plc Reports Third Quarter 2018 Financial Results
    PR Newswirelast month

    Perrigo Company plc Reports Third Quarter 2018 Financial Results

    DUBLIN , Nov. 8, 2018 /PRNewswire/ -- Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion , reported net loss of $68 million compared to a net income of $45 million last year ...

  • Benzingalast month

    Perrigo Q3 Earnings Preview

    Perrigo (NYSE: PRGO ) announces its next round of earnings this Thursday, Nov. 8. Here's Benzinga's advanced look at Perrigo's Q3 earnings report. Earnings and Revenue Wall Street analysts see Perrigo ...

  • What's in the Cards for Perrigo (PRGO) This Earnings Season?
    Zackslast month

    What's in the Cards for Perrigo (PRGO) This Earnings Season?

    Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.